Pfizer announced on Tuesday it will allow low and middle-income countries to make and distribute the company’s COVID-19 pill inexpensively. The move is an attempt to increase the global supply in 95 poorer nations.
While the deal helps treat patients, the company has not made the same decision when it comes to its COVID-19 vaccine.
Axios Re:Cap host Felix Salmon is joined by Axios health care business reporter Bob Herman to discuss Pfizer’s decisions and the global ramifications.
